CKD Bio Corp. (063160.KS)

KRW 22500.0

(-1.96%)

Market Cap (In KRW)

123.43 Billion

Revenue (In KRW)

160.35 Billion

Net Income (In KRW)

-24.19 Billion

Avg. Volume

43.17 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
19710.0-35700.0
PE
-
EPS
-
Beta Value
1.134
ISIN
KR7063160006
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Hui Yil Kang
Employee Count
-
Website
https://www.ckdbio.com
Ipo Date
2000-01-04
Details
CKD Bio Corp. manufactures and distributes drug substances based on fermentation, synthesis, and biotechnology in South Korea. It offers drug substances in the areas of antibiotic, ß-lactamase inhibitors, immunosuppressants, anticancer drugs, obesity treatment drugs, dry eye, antivirus, antituberculosis, antihyperlipidemics, and probiotics. The company also provides contract research and development, and manufacturing services for active pharmaceutical ingredients and intermediates, and probiotics. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.